Australia has a long standing position as an global leader in the clinical trial space. There is a plethora of reasons making Australia a desirable destination for clinical trials. The R&D tax incentives scheme is available to foreign stakeholders, the regulatory environment is advantageous with no IND required, a universal healthcare system that supports clinical research and start up timelines are short with seamless central ethics approval processes. This is further enhanced by an international reputation of hard work, quality and care in the biomedical industry.
As well as being a global leader in clinical trials, Australia has a recognised strength in neuroscience. Victoria is the epicentre of neuroscience research, led by The Florey Institute of Neuroscience and Mental Health, located in Melbourne’s research hub known as the Parkville precinct. Within this sits Neuroscience Trials Australia (NTA), a unique and niche CRO.
A key distinction within the Australian neuroscience clinical trial landscape is the neuroscience trial network. NTA is deeply embedded in the network. This unique position affords numerous benefits, including keeping an up to date capabilities database which assists with feasibility assessments and co-bids for projects. The network is comprehensive, spaning across stroke, movement disorders, epilepsy, dementia, multiple sclerosis, neuromuscular, neurosurgery and pain.
“We pride ourselves on our personalised service, working with our networks and staying with the client end-to-end. We find clients enjoy working with a dedicated service provider who work together with the client on the whole process”, said Dr Tina Soulis, NTA General Manager.
Dr Soulis is passionate about ensuring NTA staff have broad skill sets, and also maintaining key relationships within the industry and the healthcare provider environment. “This approach, and what we can offer mitigates risks, and I believe it’s for these reasons we have such a high client return rate”, she said.
NTA project manage and monitor phase 1, 2 and 3 clinical trials, this includes drugs and devices. We also work with the Government and patience advocacy groups – with a specialled body of knowledge in a niche field we hold key relationships within the industry.